Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: Preliminary results

Journal of Computer Assisted Tomography

Volumn 35, Issue 6, 2011, Pages 723-727

  Nakamura, Yuko ^a   Toyota, Naoyuki ^b   Shuji Date, ^a   Oda, Seitaro ^c   Namimoto, Tomohiro ^c   Yamashita, Yasuyuki ^c   Beppu, Toru ^c   Awai, Kazuo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b National Hospital Kure Medical Center   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

gadoxetate disodium; hepatic MRI; hepatobiliary phase; hepatocellular carcinoma; transitional phase

Indexed keywords

DIAGNOSIS; GADOLINIUM COMPOUNDS; TUMORS;

EMBOLIZATION; GADOXETATE; GADOXETATE DISODIUM; HEPATIC MRI; HEPATIC TUMORS; HEPATOBILIARY; HEPATOBILIARY PHASE; HEPATOCELLULAR CARCINOMA; SIGNAL INTENSITIES; TRANSITIONAL PHASE;

MAGNETIC RESONANCE IMAGING;

GADOXETIC ACID;

ADULT; AGED; ARTERIOVENOUS SHUNT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER PATIENT; CANCER SIZE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOLOGY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; RADIOLOGIST; TUMOR EMBOLISM;

EID: 81355123477     PISSN: 03638715     EISSN: 15323145     Source Type: Journal    
DOI: 10.1097/RCT.0b013e3182372c40     Document Type: Article

References (28)

1. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275. (Pubitemid 37549812)
2. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
3. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256:806-816.
4. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005;237:89-98. (Pubitemid 41346150)
5. Dahlstrom N, Persson A, Albiin N, et al. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects. Acta Radiol. 2007;48:362-368. (Pubitemid 46633865)
6. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
7. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467. (Pubitemid 351248177)
8. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CTVinitial observations. Radiology. 2005;234:468-478. (Pubitemid 40139918)
9. Reimer P, Tombach B, Daldrup H, et al. [New MR contrast media in liver diagnosis. Initial clinical results with hepatobiliary Eovist (gadolinium-EOB-DTPA) and RES-specific Resovist (SH U 555 A)]. Radiologe. 1996;36:124-133.
10. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996;200:59-67. (Pubitemid 26197732)
11. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199:177-183. (Pubitemid 26098637)
12. Foley WD. Dynamic hepatic CT. Radiology. 1989;170:617-622. (Pubitemid 19062569)
13. Foley WD, Hoffmann RG, Quiroz FA, et al. Hepatic helical CT: contrast material injection protocol. Radiology. 1994;192:367-371. (Pubitemid 24233912)
14. Bae KT, Heiken JP, Brink JA. Aortic and hepatic peak enhancement at CT: effect of contrast medium injection rateVpharmacokinetic analysis and experimental porcine model. Radiology. 1998;206:455-464. (Pubitemid 28112962)
15. Malone D, Zech C, Ayuso C, et al. Magnetic resonance imaging of the liver: consensus statement from the 1st International Primovist User Meeting. Eur Radiol. 2008;18(suppl 4):S849-S864.
16. Tanimoto A, Lee JM, Murakami T, et al. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol. 2009;19(suppl 5): S975-S989.
17. Zech CJ, Herrmann KA, Reiser MF, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci. 2007;6:43-52.
18. Itai Y, Furui S, Ohtomo K, et al. Dynamic CT features of arterioportal shunts in hepatocellular carcinoma. AJR Am J Roentgenol. 1986;146:723-727. (Pubitemid 16117262)
19. Byun JH, Kim TK, Lee CW, et al. Arterioportal shunt: prevalence in small hemangiomas versus that in hepatocellular carcinomas 3 cm or smaller at two-phase helical CT. Radiology. 2004;232:354-360. (Pubitemid 38971271)
20. Gonen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001;221:763-767. (Pubitemid 33101770)
21. Hwang GJ, Kim MJ, Yoo HS, et al. Nodular hepatocellular carcinomas: detection with arterial-, portal-, and delayed-phase images at spiral CT. Radiology. 1997;202:383-388. (Pubitemid 27051731)
22. Mitsuzaki K, Yamashita Y, Ogata I, et al. Multiple-phase helical CT of the liver for detecting small hepatomas in patients with liver cirrhosis: contrast-injection protocol and optimal timing. AJR Am J Roentgenol. 1996;167:753-757. (Pubitemid 26279730)
23. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4:1-9.
24. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPAYenhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20:2405-2413.
25. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009;44:793-798.
26. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imagingVcorrelation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology. 2010;255:824-833.
27. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imagingVcorrelation with molecular transporters and histopathologic features. Radiology. 2010;256:817-826. E-pub July 27, 2010.
28. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPAYenhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042-1046.